Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Edgewise Q3 results: EDG-7500 Phase 3 on track; EDG-15400 dosing begins; strong cash

Nov 4, 2026, 4:11 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong near-term catalysts include EDG-7500 Phase 3 initiation by year-end and a substantial cash influx from the sevasemten sale, which de-risks financing for ongoing trials.

AI summary

What happened, with direct paths to the underlying reporting

Edgewise reported its Q3 2026 results with continued progress across its cardiovascular programs. The company highlighted positive CIRRUS-HCM data and a JCI Insight publication supporting EDG-7500's differentiated profile, with a Phase 3 initiation expected by year-end 2026. EDG-15400 began dosing in EQUINOX-HFpEF, while a Sevasemten sale to Servier produced a $1.348B gain, strengthening Edgewise's balance sheet and cash runway.

Q3 2026 results show progress across EDG-7500 and EDG-15400.
EDG-7500 Phase 3 on track to initiate by year-end 2026.
Dosed first patient in EDG-15400 EQUINOX-HFpEF Phase 2.
Sevasemten sale to Servier completed; $1.348B gain boosts cash.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.